NCT03133546 2026-02-06
BOOSTER
ETOP IBCSG Partners Foundation
Phase 2 Completed
Clinical Trials
16 trialsNCT04184921 2026-02-03
Combination of Osimertinib and Aspirin to Treat EGFR Mutation NSCLC Patients
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Phase 2 Completed
NCT02442349 2026-01-09
AURA17
AstraZeneca
Phase 2 Completed
NCT03414814 2025-02-11
Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutation
Seoul National University Hospital
Phase 2 Completed
NCT04233021 2025-02-03
ORBITAL
Intergroupe Francophone de Cancerologie Thoracique
Phase 2 Completed
NCT02841579 2025-01-28
AZENT
MedSIR
Phase 2 Completed
NCT03732352 2024-11-12
18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients with EGFR Activated Recurrent Glioblastoma
Jonsson Comprehensive Cancer Center
Phase 2 Completed
NCT02094261 2024-11-06
AURA2
AstraZeneca
Phase 2 Completed
NCT04764214 2024-08-19
SRT for Residual Oligometastases of NSCLC After 3rd Generation EGFR-TKIs
Fudan University
Phase 2 Completed
NCT02759835 2024-06-07
Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT03497767 2024-05-31
OUTRUN
Trans Tasman Radiation Oncology Group
Phase 2 Completed
NCT03810066 2024-05-09
Exploring the Theragnostic Value of Osimertinib in EGFR-mutated Lung Cancer (THEROS)
University Hospital, Essen
Phase 2 Completed
NCT03434418 2023-10-17
A Study Osimertinib in Patients With Stage 4 Non-small Cell Lung Cancer With Uncommon EGFR Mutations
Duke University
Phase 2 Completed
NCT02769286 2021-08-03
LiquidLung-O
Chonnam National University Hospital
Phase 2 Completed
NCT03394118 2021-04-27
TAGRISSO (Osimertinib) in NSCLC Patients in Whom T790 Mutations Are Detected by Liquid Biopsy
Asan Medical Center
Phase 2 Completed
NCT02179671 2019-08-02
Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer
AstraZeneca
Phase 2 Completed